SUMMARY The locomotor function of polymorphonuclear cells (cellular chemotaxis) and serum chemotactic activity (humoral chemotaxis) were studied in 51 patients with Crohn's disease using a method of migration under agarose gel. To study cellular chemotaxis patient's polymorphonuclear cells were challenged against normal Zymosan activated serum and humoral chemotaxis was evaluated testing the patient's Zymosan activated serum against normal polymorphonuclear cells.
Leucocyte chemotaxis is one of the early stages of the phagocytic process which is the basic mechanism in the clearance of particulate or antigenic materials.
In Crohn's disease a defective clearance has been suggested as one of the underlying pathogenetic mechanisms of the chronic inflammation.' Furthermore, the high prevalence of abscesses and fistulae in this condition suggests that defects in local defence mechanisms may occur during the natural history of the disease.
In studies using the skin window technique, Segal and Loewi2 reported in Crohn's disease a defective neutrophil function 'in vivo. ' Received for publication 20 January 1981. In the present investigation the locomotor function of polymorphonuclear cells (cellular chemotaxis) as well as the complement derived serum chemotactic activity (humoral chemotaxis) were studied in Crohn's disease patients using a new method4 of migration under agarose gel.
As we have already described4`a defective chemotactic function in patients with hypogammaglobulinaemia and/or IgA deficiency, the serum immunoglobulin levels were also considered in the study. Medical treatment, when given, consisted of corticosteroids and/or sulphasalazine (Salazopyrin (SAP)). Twenty-nine patients were receiving corticosteroids at the time of the study: mean dose 17 mg/day prednisone (range 5-25 mg) for a mean period of 5.5 months (range three to 10). Nine of these patients were also receiving SAP. Four patients were receiving only SAP at the time of the study. Local complications were present in 16 patients: enterocutaneous fistulae, eight; enteroenteric fistulae, three; obstruction, two; anal lesions, three; abscesses, two. Two patients had systemic complications: ankylosing spondylitis, one, and pyoderma gangrenosum, one.
Methods

CONTROLS
Fifty-one healthy volunteers of comparable age and sex distribution were studied as a control group. An additional 12 patients with different chronic diseases (ulcerative colitis, five; chronic active hepatitis, two; systemic lupus erythematosus, three; asthma, two) chronically treated with steroids were also considered.
The results of liver function tests were within the normal ranges in all patients and control subjects.
Cell isolation Samples of 10 ml heparinised sterile blood were centrifuged at 200 g for 15 minutes in polystyrene test tubes. The plasma and buffy coat leucocytes were transferred to another tube and separated by gravity sedimentation at 37°C in a mixture of air (95%) and CO2 (5%) for 45 minutes. The leucocyte-rich supernatant was then layered on Ficoll-Isopaque density gradient and centrifuged at 900 g for 30 minutes. The PMN were collected from the bottom and resuspended in 3 ml of medium (TC 199, RPMI 1640, Flow Laboratories). The cells were washed twice and the erythrocyte contamination was eliminated by lysis with buffered ammonium chloride. The cells were finally resuspended at a concentration of 30 x 106/ml. The medium used for resuspension was the same as that used for preparation ofagarose plates.
Collection ofserum and activation Both plasma EDTA and fresh serum samples were collected. For activation the fresh serum was incubated for 30 minutes at 37°C with Zymosan (Sigma Chemical Co) 50 mg/ml. It was then centrifuged at 700 g for 10 minutes and the supernatant collected.
Preparation ofagarose plates Agarose (Reo 15, Boehring) was dissolved in TC 199 or RPMI 1640 by heating in a boiling water bath at a concentration of 1 .2%. After cooling to 45°-50°C, the agarose medium was supplemented with 10% of fetal calf serum (Colorado serum Co) and 1.5 of this solution was poured into a 35 mm tissue culture dish (3001, Falcon) and allowed to harden. Three wells (4 mm in diameter and spaced 2 mm apart) were cut, using a suitable template punch prepared by us. The agarose plugs were removed by means of a Pasteur pipette attached to a vacuum line.
Leucocyte chemotaxis assay
The tests were carried out in duplicate: 10 ,ul of the cell suspension was added to the central well and 10 ,ul of activated serum to one of the lateral wells. The other wells was filled with 10 ,ul of TC 199 or RPMI 1640. The dishes were covered and placed in a 37°C humid atmosphere with 5% of CO2 for three hours. The preparations were then fixed with May-Grunwald for 30 minutes, the layer of the agarose was removed, and the plates stained with Giemsa. The migrated cells were counted in a Leitz Orthoplan microscope using x 10 eye-piece grid (side 1 cm) with a x 10 magnification. The number of cells which had migrated towards the non-attracting pole, which are considered to have undergone random locomotion, was subtracted. After the preparation had been projected with a Leitz microprojector (magnification scale 1:175) the maximum distance of migration was measured and the distance of random locomotion was subtracted. The measurement was then multiplied by the number of cells and divided by 100. 
Results
No significant difference was found between healthy controls and Crohn's disease patients as far as the mean values of polymorphonuclear cellular chemotaxis are concerned (Table 1) . However nine out of the 51 Crohn's disease patients had a migration index below the lower normal limit, while, in seven patients, a migration index above the upper normal limit was observed (Fig. 1) . No correlation was found between cellular chemotaxis values and site and extent of bowel involvement, disease activity, and occurrence of complications. Seven out of nine Crohn's disease patients with low values were receiving steroid treatment at the time of the study. No low values were found in the steroid treated control group.
The mean values of humoral chemotaxis-that is, complement derived serum chemotactic activitywere significantly lower in Crohn's disease patients than in the healthy controls (Table) . Again, no significant correlation was found between migration index and disease activity, occurrence of complications, and site of bowel involvement. However when the humoral chemotaxis values were correlated with the medical treatment (Fig. 2) a significantly lower mean value of migration index was observed in the steroid treated Crohn's disease patients.
The mean values of IgG, IgA, and IgM were not significantly different from those of the normal controls. No significant difference was found between steroid treated and non-treated patients, as far as the serum Ig levels were concerned (Fig. 3) .
Mean values of plasma EDTA C3, were normal, although nine out of 48 patients had C3, levels above the upper normal limit. C4 levels were within the normal range in all patients (Fig. 3) .
Discussion
The results of this study show that in Crohn's In summary, the present results suggest that a defective complement derived serum chemotactic activity may occur in some patients during steroid treatment. These findings may offer an explanation for the therapeutic effect of corticosteroids in Crohn's disease. On the other hand, as already speculated by Segal and Loewi,2 they suggest that steroid treatment might play a role in promoting chronicity.
Additional studies are necessary on the possible relationship between chemotactic function, medical treatment, and the natural history of Crohn's disease.
